If you have been reading about Reversed-phase HPLC and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2026-02-28. Numbers and descriptions here follow the published literature rather than marketing material.
Identity and purity testing for thymosin alpha 1 relies mainly on reversed-phase high-performance liquid chromatography and mass spectrometry. Chromatography separates the parent peptide from truncated or modified variants, while mass spectrometry confirms the expected molecular mass. Amino acid analysis and peptide mapping provide additional sequence confirmation. Counterion content, water content, and residual solvents are measured separately as part of specification testing. No single method captures every attribute, so laboratories combine several techniques.
The peptide lacks cysteine, methionine, and tryptophan, so disulfide scrambling and sulfur oxidation are not major degradation routes. Instead, aspartate residues can undergo isomerization or cyclization to succinimide intermediates, generating isoaspartate variants. Hydrolysis of peptide bonds also occurs slowly in solution. These changes may reduce biological activity even when the main peak remains detectable. Stability studies therefore track both potency and the appearance of related substances.
Clinical interest has centered on chronic viral hepatitis, on immune restoration in various conditions, and on use as an adjuvant intended to improve responses to vaccines. Trials have reported mixed results, and regulatory status differs sharply between countries; in some places it is a prescription product, while elsewhere it is sold without an approved therapeutic indication. Because published studies vary widely in design, population, and endpoints, comparisons across them are difficult and no single conclusion covers the whole literature.
Thymosin alpha 1 is a short peptide of 28 amino acid residues that derives from the amino terminal region of a larger precursor protein known as prothymosin alpha. The peptide carries an acetyl group on its first residue and contains no disulfide bonds or carbohydrate chains. Its sequence is highly conserved across mammalian species, which is one reason laboratories treat it as a molecule with a defined and reproducible structure rather than a variable tissue extract. The name follows an early naming convention for thymus-derived fractions and does not imply that the peptide acts as a hormone in the classical endocrine sense.
Biologically, the peptide is studied mainly in the context of immune cell development and regulation. It is produced in the thymus and in several other tissues, and it appears to influence the maturation and activity of T cells and other immune populations. Laboratory work describes effects on cytokine production, on the balance between T cell subsets, and on the function of dendritic cells. Much of this evidence comes from cell culture and animal models, so the extent to which the same pathways operate in humans remains an open question.
| Property | Value | Notes |
|---|---|---|
| Physical form | Lyophilized powder | Reconstituted before use |
| Typical storage | 2-8 °C, protected from light | Applies to the powder |
| Reconstitution solvent | Sterile water or saline | Follow product labeling |
| Solution stability | Shorter than the powder | Refrigerate and use promptly |
| Primary purity method | Reversed-phase HPLC | Detects related substances |
Quality control for thymosin alpha-1 focuses on identity, purity, and potency. Identity is confirmed by mass spectrometry and amino acid analysis, while purity is assessed by chromatography with limits on related substances and residual solvents. Potency assays may use cell-based immune readouts, but these are not standardized across laboratories. Regulatory status differs by jurisdiction; no product is approved in the United States for clinical use, whereas some other countries register injectable forms for specific indications.
Quantifying thymosin alpha-1 in a sample usually relies on reverse-phase high-performance liquid chromatography. The peptide lacks strong chromophores, so detection often occurs at 214 nm, where the peptide backbone absorbs. Mass spectrometry provides confirmatory identification and can detect sequence variants or truncations. Immunoassays have been used in biological matrices, but they may cross-react with related fragments. For purity assessment, chromatographic peak area gives the main component percentage, while mass accuracy verifies molecular identity.
The molecule consists of 28 amino acid residues with an acetyl group attached to the N-terminal serine. Its sequence is acidic overall, with several glutamic and aspartic acid residues distributed along the chain and no cysteine, so disulfide bridges do not form. The peptide carries a net negative charge at physiological pH. Because the N-terminus is blocked, the intact molecule resists degradation by many aminopeptidases, which contributes to its stability in biological fluids.
The peptide is generated in cells by cleavage of prothymosin alpha, a larger acidic protein encoded by the PTMA gene. Prothymosin alpha is expressed in many tissues, not only in the thymus, and its functions include nuclear roles in chromatin-related processes. The 28-residue fragment corresponds to the N-terminal portion of that precursor. How the cleavage occurs and how the fragment's concentration is regulated remain open questions; circulating amounts are small and difficult to measure reliably with routine assays.
Thymosin alpha 1 is a short peptide first isolated from bovine thymus tissue in the early 1970s during fractionation work aimed at identifying factors that influence T cell development. It belongs to a family of acidic thymic peptides, and the original preparations contained several components that were later separated by chromatography. The compound is now produced synthetically rather than extracted from tissue, which removes batch variability tied to animal sourcing. Researchers describe it as an immunomodulatory peptide because laboratory studies show effects on several cell types of the innate and adaptive immune systems.
== Postnatal tolerance to NIMAs == NIMA-specific tolerance causes some interesting immunological phenotypes: sensitization to erythrocyte Rhesus factor (Rh) antigens is reduced among Rh- women born to Rh+ women, long-term kidney allograft survival is improved in NIMA-matched donor-recipient sibling pairs, or acuteness of bone marrow transplantation graft-versus-host disease is reduced, when recipients of donor stem cells are NIMA-matched. Cross-fostering animal studies show that when postnatal NIMA exposure though breastfeeding is eliminated, survival of NIMA-matched allografts is reduced. This suggests that to maintain NIMA-specific tolerance in offspring, breastfeeding is essential, but ingestion of mother's cells alone does not prime NIMA-specific tolerance. Both prenatal and postnatal exposure to mother's cells is required to maintain NIMA-specific tolerance.
Born into a Democratic-voting family, Sanders was first introduced to political activism when his brother Larry joined the Young Democrats of America and campaigned for Adlai Stevenson II in 1956. Sanders joined Vermont's Liberty Union Party in 1971 and was a candidate for several offices, never coming close to winning election. He became party chairman, but quit in 1977 to become an independent. In 1980, he served as an elector for the Socialist Workers Party. In 1981, Sanders ran as an independent for mayor of Burlington, Vermont, and defeated the Democratic incumbent; he was reelected three times. Although an independent, he endorsed Democratic presidential candidates Walter Mondale in 1984 and Jesse Jackson in 1988. His endorsement of Mondale was lukewarm (telling reporters that "if you go around saying that Mondale would be a great president, you would be a liar and a hypocrite"), but he supported Jackson enthusiastically. The Washington Post reported that the Jackson campaign helped inspire Sanders to work more closely with the Democratic Party.Sanders attended the 1983 conference of the Socialist Party USA where he gave a speech. Sanders first ran for the US House of Representatives in 1988 and for the US Senate in 2006, often adopting a strategy of winning the Democratic Party primary, thereby eliminating Democratic challengers, and then running as an independent in the general election. He continued this strategy through his reelection in the 2018 United States Senate election in Vermont. Throughout his tenure in Congress, he has been listed as an independent.
[NH4]2CO3 + CaSO4 → [NH4]2SO4 + CaCO3 Ammonium sulfate occurs naturally as the rare mineral mascagnite in volcanic fumaroles and due to coal fires on some dumps. Ammonium sulfate is a byproduct in the production of methyl methacrylate (CH2=C(CH3)COOCH3).
==== Hydrogenation of carbon dioxide ==== The catalytic hydrogenation of CO2 to formic acid has long been studied. This reaction can be conducted homogeneously. Electrolytic reduction of CO2 to formate has been investigated but not commercialized.
== Disorders and conditions == Numerous reports have been published indicating that the glutamate/GABA–glutamine cycle is compromised in a variety of neurological disorders and conditions. Biopsies of sclerotic hippocampus tissue from human subjects with epilepsy have shown decreased glutamate–glutamine cycling. Another pathology in which the glutamate/GABA–glutamine cycle might be compromised is Alzheimer's disease; NMR spectroscopy showed decreased glutamate neurotransmission activity and TCA cycling rate in patients with Alzheimer's disease. Hyperammonemia in the brain, typically occurring as a secondary complication of primary liver disease and known as hepatic encephalopathy, is a condition that affects glutamate/GABA–glutamine cycling in the brain. Current research into autism also indicates potential roles for glutamate, glutamine, and/or GABA in autistic spectrum disorders.
Sources: en.wikipedia.org
As lieutenant governor in 2016, Newsom was the official proponent of Proposition 63. The ballot measure required a background check and California Department of Justice authorization to purchase ammunition, among other gun control regulations. In response to the 2019 mass shooting in Virginia Beach, Newsom called for nationwide background checks on people purchasing ammunition. Later that year, he responded to the Gilroy Garlic Festival shooting by stating his support for the Second Amendment and saying he would like national cooperation controlling "weapons of goddamned mass destruction". He also said, "These shootings overwhelmingly, almost exclusively, are males, boys, 'men'—I put in loose quotes. I do think that is missing in the national conversation." On June 10, 2021, Newsom called federal Judge Roger Benitez "a stone cold ideologue" and "a wholly owned subsidiary of the gun lobby of the National Rifle Association" after Benitez struck down California's statewide ban on assault weapons. While the ban remained in place as the state appealed the ruling, Newsom proposed legislation that would empower private citizens to enforce the ban after the United States Supreme Court declined to strike down the Texas Heartbeat Act, which empowers private citizens to report unauthorized abortions. In 2022, Newsom signed gun control bills passed by the California Legislature.
==== Removal of N-terminal methionine ==== The initiating methionine (and, in bacteria, fMet) may be removed during translation of the nascent protein. For E. coli, fMet is efficiently removed if the second residue is small and uncharged, but not if the second residue is bulky and charged. In both prokaryotes and eukaryotes, the exposed N-terminal residue may determine the half-life of the protein according to the N-end rule.
=== In humans === Xylazine is absorbed, metabolized, and eliminated rapidly. It can be inhaled or administered intravenously, intramuscularly, subcutaneously, or orally either by itself or in conjunction with other anesthetics, such as ketamine, barbiturates, chloral hydrate, and halothane in order to provide reliable anesthesia effects. The most common route of administration is injection. Xylazine's action can be seen usually 15–30 minutes after administration and the sedative effect may continue for 1–2 hours and last up to 4 hours. Once xylazine gains access to the vascular system, it is distributed within the blood, allowing it to enter the heart, lungs, liver, and kidneys. In non-fatal cases, the blood plasma concentrations range from 0.03 to 4.6 mg/L. Xylazine diffuses extensively and penetrates the blood–brain barrier, since the molecule does not have a charge and dissolves in lipids. Xylazine is metabolized by the liver's cytochrome P450 enzymes. When it reaches the liver, xylazine is metabolized and proceeds to the kidneys to be excreted in urine. Around 70% of a dose is excreted unchanged. Thus, urine can be used in detecting xylazine administration because it contains many metabolites, which are the main targets and products in urine. Within a few hours, xylazine decreases to undetectable levels. Other factors can also significantly impact the pharmacokinetics of xylazine, such as sex, nutrition, environmental conditions, and prior diseases.
A multiple-sequence FASTA format, or multi-FASTA format, would be obtained by concatenating several single-sequence FASTA files in one file. This does not imply a contradiction with the format as only the first line in a FASTA file may start with a ";" or ">", forcing all subsequent sequences to start with a ">" in order to be taken as separate sequences (and further forcing the exclusive reservation of ">" for the sequence definition line). Thus, the examples above would be a multi-FASTA file if taken together. Modern bioinformatics programs that rely on the FASTA format expect the sequence headers to be preceded by ">". The sequence is generally represented as "interleaved", or on multiple lines as in the above example, but may also be "sequential", or on a single line. Running different bioinformatics programs may require conversions between "sequential" and "interleaved" FASTA formats.
Refers to maintaining the confidentiality of trial participants including their personal identity and all personal medical information. The trial participants' consent to the use of records for data verification purposes should be obtained prior to the trial and assurance must be given that confidentiality will be maintained. (NLM) Prevention of disclosure, to other than authorized individuals, of a sponsor's proprietary information or of a subject's identity. (ICH E6) Consecutive case series
Sources: en.wikipedia.org
The lyophilized powder is kept refrigerated at 2 to 8 degrees Celsius and protected from light. Reconstituted solutions should be used promptly. Freezing and thawing repeatedly is avoided.
Reversed-phase HPLC is the primary tool for purity, paired with mass spectrometry for identity. Amino acid analysis and peptide mapping add sequence confirmation. Several techniques are combined because no single test covers every attribute.
It lacks sulfur-containing residues, so oxidation is limited. Aspartate isomerization and slow hydrolysis are the main concerns. Solution stability is shorter than that of the lyophilized powder.
The name reflects an early convention for naming thymus-derived fractions. The peptide is characterized and measured as a defined molecule, and it does not operate through a single classical endocrine axis.